+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anemia and Other Blood Disorder Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery

  • ID: 4856001
  • Report
  • October 2020
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbvie Inc.
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • FibroGen Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Anemia and Other Blood Disorder Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global anemia and other blood disorder drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the anemia and other blood disorder drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Anemia and Other Blood Disorder Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive land scape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive land scape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered: 1) By Type: Iron Deficiency Anemia; Chronic Kidney Disease Anemia; Sickle Cell Anemia; Aplastic Anemia
2) By Distribution Channel: Hospitals Pharmacy; Online Pharmacy; Pharmacy
3) By Route of Administration: Oral; Injectable
4) By Anemia Type: Microcytic (Low MCV); Normocytic (Normal MCV); Macrocytic (High MCV)

Companies Mentioned: Amgen; GlaxoSmithKline plc; Akebia therapeutics; Bayer AG ; Pfizer

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie Inc.
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • FibroGen Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
1. Executive Summary

2. Anemia And Other Blood Disorder Drugs Market Characteristics

3. Anemia And Other Blood Disorder Drugs Market Size And Growth
3.1. Global Anemia And Other Blood Disorder Drugs Historic Market, 2015-2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Anemia And Other Blood Disorder Drugs Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Anemia And Other Blood Disorder Drugs Market Segmentation
4.1. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Iron Deficiency Anemia
  • Chronic Kidney Disease Anemia
  • Sickle Cell Anemia
  • Aplastic Anemia
4.2. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospitals Pharmacy
  • Online Pharmacy
  • Pharmacy
4.3. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Oral
  • Injectable
4.4. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Anemia Type , Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Microcytic (Low MCV)
  • Normocytic (Normal MCV)
  • Macrocytic (High MCV)
5. Anemia And Other Blood Disorder Drugs Market Regional And Country Analysis
5.1. Global Anemia And Other Blood Disorder Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Anemia And Other Blood Disorder Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Anemia And Other Blood Disorder Drugs Market
6.1. Asia-Pacific Anemia And Other Blood Disorder Drugs Market Overview
6.2. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Anemia And Other Blood Disorder Drugs Market
7.1. China Anemia And Other Blood Disorder Drugs Market Overview
7.2. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Anemia And Other Blood Disorder Drugs Market
8.1. India Anemia And Other Blood Disorder Drugs Market Overview
8.2. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Anemia And Other Blood Disorder Drugs Market
9.1. Japan Anemia And Other Blood Disorder Drugs Market Overview
9.2. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Anemia And Other Blood Disorder Drugs Market
10.1. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Anemia And Other Blood Disorder Drugs Market
11.1. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Anemia And Other Blood Disorder Drugs Market
12.1. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Anemia And Other Blood Disorder Drugs Market
13.1. Western Europe Anemia And Other Blood Disorder Drugs Market Overview
13.2. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Anemia And Other Blood Disorder Drugs Market
14.1. UK Anemia And Other Blood Disorder Drugs Market Overview
14.2. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Anemia And Other Blood Disorder Drugs Market
15.1. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Anemia And Other Blood Disorder Drugs Market
16.4. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Anemia And Other Blood Disorder Drugs Market
17.1. Eastern Europe Anemia And Other Blood Disorder Drugs Market Overview
17.2. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Anemia And Other Blood Disorder Drugs Market
18.1. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Anemia And Other Blood Disorder Drugs Market
19.1. North America Anemia And Other Blood Disorder Drugs Market Overview
19.2. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Anemia And Other Blood Disorder Drugs Market
20.1. USA Anemia And Other Blood Disorder Drugs Market Overview
20.2. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Anemia And Other Blood Disorder Drugs Market
21.1. South America Anemia And Other Blood Disorder Drugs Market Overview
21.2. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Anemia And Other Blood Disorder Drugs Market
22.1. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Anemia And Other Blood Disorder Drugs Market
23.1. Middle East Anemia And Other Blood Disorder Drugs Market Overview
23.2. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Anemia And Other Blood Disorder Drugs Market
24.1. Africa Anemia And Other Blood Disorder Drugs Market Overview
24.2. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Anemia And Other Blood Disorder Drugs Market Competitive Landscape And Company Profiles
25.1. Anemia And Other Blood Disorder Drugs Market Competitive Landscape
25.2. Anemia And Other Blood Disorder Drugs Market Company Profiles
25.2.1. Amgen Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. GlaxoSmithKline plc
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Akebia therapeutics
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Bayer AG
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Pfizer, Inc.
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market

27. Anemia And Other Blood Disorder Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Anemia And Other Blood Disorder Drugs Market Future Outlook and Potential Analysis

30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. About the Publisher
30.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie Inc.
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • FibroGen Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
The anemia and other blood disorder drugs market consists of sales of anemia and other blood disorder drugs and related services. Anemia and other blood disorder drugs that are used to stimulate red blood cell production or hemoglobin in the human body that includes Erythropoietin (Epoetin alpha), Ferrous Sulfate, Iron Dextran, Deferoxamine, Immunosuppressant, Bone marrow stimulants, Corticosteroids, Aminoxin, Hespan, Hextend and Pyridoxine. The market also comprises of sales of drugs that are responsible for curing other blood disorders, including inherited orphan blood disorder.

The global anemia and other blood disorder drugs market is expected to decline from $50.8 billion in 2019 to $50.7 billion in 2020 at a compound annual growth rate (CAGR) of -0.2%. The decline is mainly due to restrictions due to the coronavirus disease 2019 (COVID-19) pandemic and the measures to contain it. Some medical centers have canceled treatments, somehow put on hold, some have altered the policies and procedures to provide services. Also, many companies in the hematology drug market halted their business operations. All these factors have impacted the market growth. The market is then expected to recover and grow at a CAGR of 13.5% from 2021 and reach $84.4 billion in 2023.

North America was the largest region in the anemia and other blood disorder drugs market in 2018. The anemia and other blood disorder drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, in the year 2017, anemia was found to be most frequent disease in elderly population (> 65 years of age), reaching a prevalence rate of around 17%. In 2014, the World Bank reported that anemia is the 8th leading cause of disease among the women and young population. Growth in prevalence rate of anemia drives the market.

There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids or a combination of these substances or might be derived from living organisms like humans, animals or microorganisms or that may contain components of living organisms. The growth in use of biologics over the drugs restricts the market resulting in decline of amount of drugs being used for the treatment of anemia & other blood disorders. For example, in 2015 Hospira, a medical device and pharmaceutical company submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, on May 2018, FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. The increase in use of biologics will hamper the growth of the market.

Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology and cost. Such collaborations are also helpful to the companies in case of expiring licenses and stringent regulatory environment. For example, in 2017, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. entered into an agreement to manufacture and commercialize Vadadustat, an oral HIF stabilizer, used for the treatment of anemia. Another such example is, Cipla collaborating with Hetero Drugs for developing a biosimilar for anemia drug in the year 2014.

The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get their drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark.

In 2019, AMAG Pharmaceutical, an American pharmaceutical company agreed to acquire Perosphere for $415 million. The acquisition would result in expanding AMAG's pipeline and enhance its presence in Hematology drugs market with the help of Perosphere's next-generation Anticoagulant reversal agent called Ciraparantag. Perosphere is a specialty pharmaceutical company focusing on rescue drug medications. The Company was established in 2011 and is headquartered in Danbury, Connecticut, USA.

Major players in the market are Amgen Inc., GlaxoSmithKline plc, Akebia therapeutics, Bayer AG and Pfizer, Inc.
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Akebia therapeutics
  • Bayer AG
  • Pfizer Inc.
  • Regen biopharma
  • Hoffmann-La Roche Ltd.
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Janssen Pharmaceutical
  • Global Blood Therapeutics (GBT)
  • GlycoMimetics
  • Eli Lilly
  • Fibrogen
  • Bluebird bio
  • Acceleron Pharma
  • AMAG Pharmaceuticals
  • Pieris Pharmaceuticals
  • Vifor Pharma Management Ltd.
  • FibroGen Inc.
  • Sanofi
  • Allergan Inc.
  • Meda Cuonsumer Healthcare Inc.
  • Abbvie Inc.
  • Johnson and Johnson
  • Daiichi Sankyo
  • Galenica
  • Pharmacosmos
  • Keryx Biopharmaceuticals Inc.
  • Emmaus Medical Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll